Ancient medicinal clay shows promise against today's worst bacterial infections

Naturally occurring clay from British Columbia, Canada - long used by the region's Heiltsuk First Nation for its healing potential - exhibits potent antibacterial activity against multidrug-resistant pathogens, according to new research from the University of British Columbia.

The researchers recommend the rare mineral clay be studied as a clinical treatment for serious infections caused by ESKAPE strains of bacteria.

The so-called ESKAPE pathogens - Enterococcus faecium, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species - cause the majority of U.S. hospital infections and effectively 'escape' the effects of antibacterial drugs.

"Infections caused by ESKAPE bacteria are essentially untreatable and contribute to increasing mortality in hospitals," says UBC microbiologist Julian Davies, co-author of the paper published today in the American Society for Microbiology's mBio journal.

"After 50 years of over-using and misusing antibiotics, ancient medicinals and other natural mineral-based agents may provide new weapons in the battle against multidrug-resistant pathogens."

The clay deposit is situated on Heiltsuk First Nation's traditional territory, 400 kilometres (250 miles) north of Vancouver, Canada, in a shallow five-acre granite basin. The 400-million kilogram (400,000 tonne) deposit was formed near the end of the last Ice Age, approximately 10,000 years ago.

Local First Nations people have used the clay for centuries for its therapeutic properties - anecdotal reports cite its effectiveness for ulcerative colitis, duodenal ulcer, arthritis, neuritis, phlebitis, skin irritation, and burns.

"We're fortunate to be able to partner with UBC on this significant research program" says Lawrence Lund, president of Kisameet Glacial Clay, a business formed to market cosmetic and medicinal products derived from the clay. "We hope it will lead to the development of a novel and safe antimicrobial that can be added to the diminished arsenal for the fight against the ESKAPE pathogens and other infection-related health issues plaguing the planet."

In the in vitro testing conducted by Davies and UBC researcher Shekooh Behroozian, clay suspended in water killed 16 strains of ESKAPE bacteria samples from sources including Vancouver General Hospital, St. Paul's Hospital, and the University of British Columbia's wastewater treatment pilot plant.

No toxic side effects have been reported in the human use of the clay, and the next stage in clinical evaluation would involve detailed clinical studies and toxicity testing. Loretta Li, with UBC's Department of Civil Engineering, is conducting mineralogical and chemical analyses of the clay as well. MITACS, Kisameet Glacial Clay Inc. and the Tally Fund supported the work.

Most Popular Now

Top 20 World Pharma News of 2016

Look back at the most prominent moments from the year 2016. We are proud to announce the 20 most popular World Pharma News from 2016, the most commonly viewed news accord...

Read more

Sanofi and Boehringer Ingelheim confirm Closing of…

Sanofi and Boehringer Ingelheim confirmed that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) an...

Read more

Diabetes, heart disease, and back pain dominate US…

Just 20 conditions make up more than half of all spending on health care in the United States, according to a new comprehensive financial analysis that examines spending ...

Read more

FDA approves first drug for spinal muscular atroph…

The U.S. Food and Drug Administration has approved Spinraza (nusinersen), the first drug approved to treat children and adults with spinal muscular atrophy (SMA), a rare ...

Read more

Novartis invests in next generation therapies to r…

Novartis announced today a collaboration and option agreement with Ionis Pharmaceuticals, Inc. and its affiliate Akcea Therapeutics, Inc., to license two novel treatments...

Read more

Topical treatment activates immune system to clear…

A combination of two FDA-approved drugs - a topical chemotherapy and an immune-system-activating compound - was able to rapidly clear actinic keratosis lesions from patie...

Read more

Vaccine shows promising results for early-stage br…

Deregulation and inhibition of the immune system contributes to cancer development. Many therapeutic strategies aim to re-stimulate the immune system to recognize cancer ...

Read more

Bristol-Myers Squibb announces immunotherapy clini…

Bristol-Myers Squibb Company (NYSE:BMY) today announced a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of Bristol-Myers Squi...

Read more

Anti-aging therapies targeting senescent cells: Fa…

It's an exciting time to be an elderly mouse. Researchers believe that by removing senescent cells (cells with a persistent damage response), which naturally accumulate w...

Read more

Novo Nordisk and Glooko partner to develop digital…

Novo Nordisk and Glooko today announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabet...

Read more

FDA grants Roche's cancer immunotherapy TECENTRIQ …

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA)...

Read more

AstraZeneca and Lilly to develop second potentiall…

AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]